Drug intelligence / Profile preview

Rongmin Granules

Development stage: Unknown
Lead developer: Sichuan Defeit Pharmaceutical
Administration: Oral

Overview

Rongmin Granules (榕敏颗粒) is a traditional Chinese medicine (TCM) product developed and manufactured by Sichuan Defeit Pharmaceutical. Formulated as oral granules, it is an approved and marketed product in China. While specific pharmacological details are often proprietary in TCM formulations, Rongmin Granules is primarily indicated for the treatment of allergic rhinitis. In the context of traditional Chinese medicine, it is used to clear heat, detoxify, and alleviate allergic symptoms such as nasal congestion, itching, and sneezing. The company, Sichuan Defeit Pharmaceutical, specializes in flavonoid-based drugs and herbal extracts, which aligns with the typical composition of such anti-allergic TCM products.

Brand names: 榕敏颗粒Rongmin Granules
Other names: Rongmin Keli

Beyond the preview

Go deeper on Rongmin Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rongmin Granules.

Explore the full profile